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Abstract: A series of substituted triazin-pyridazine compounds were exhibited diverse types of biological activities and 
synthesized by different methods. These compounds were mainly tested for their anti-inflammatory, anticancer, antifungal and 
antibacterial activities. These substituted triazin-pyridazine compounds have mild to potent activities on compare with their 
appropriate reference standards.
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INTRODUCTION
Heterocyclic annelated pyridazines attract considerable 
attention, which mainly arises from the large variety of 
interesting pharmacological activities observed with pyri-
dazine derivatives [1-6]. In recent years, synthesis of novel 
pyridazinone derivatives and investigation of their chemi-
cal and biological behavior have gained more importance 
due to their biological, medicinal, and agricultural reason. 
This privileged structure attracts the interest of medicinal 
chemists as a nucleus of potential therapeutic utility and 
exhibits several pharmacological activities such as anal-
gesic, anti-inflammatory, antidepressant, antihyperten-
sive, anticonvulsant, cardiotonic, diuretic, anticancer, and 
anti-HIV activities [7-12]. In addition, pyridazinones act as 
core nucleus in various drugs e.g. Sul-mazole, Amipizone, 
Indolidan, Levosimendan,Imazodan, Pimobendan, Emor-
fazone, Zardaverine and Milrinone [13-15]. Triazole and 
its derivatives are noteworthy for their physiological and 
biological importance. They paved the attention of medic-
inal chemist due to their wide range of biological activities 
like anti-inflammatory, antiviral, antifungal, antibacterial, 
anticonvulsant and anticancerousetc [16-20]. Triazolopy-
ridazine derivatives are frequently used in biological re-
search [21,22].
Anti inflammatory and analgesic activity: Non-steroi-
dal anti-inflammatory drugs (NSAIDs) are the most com-
monly prescribed medications for the treatment and/or 
management of pain, fever, and inflammation. However, 
their long term use is linked with gastroenteropathy such 
as gastric irritation, ulceration, bleeding and renal toxic-
ity that limit their therapeutic usefulness [23]. Therefore, 
the synthesis of new compounds devoid of such side ef-
fects poses a challenging task for medicinal chemists. 
The currently used NSAIDs inhibit the synthesis of non 
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selective or selective cyclooxygenases (COX1 & COX2 
or prostaglandin, histamine and bradykinin [24-26]. It has 
been suggested that prostaglandins and bradykinins play 
a major role in the analgesia or pain. So it may be pre
dicted that the title compounds may act by inhibiting the 
synthesis of these chemical mediators involved in causing 
pain as well as inflammation [27]. The pyridazinones hav-
ing characteristic pharmacological features, relative stabil-
ity and ease of preparation contemplated us to synthesize 
some new derivatives of pyridazinones as good analgesic 
and anti-inflammatory agents. Various substituted pyri-
dazinone derivatives possessing analgesic activity along 
with other useful pharmacological properties have been 
reported. Emorfazone (4-ethoxy-2-methyl-5-morpholino- 
3(2H)-pyridazinone) is a pyridazinone derivative  which is 
currently used clinically in the management of pain and 
inflammation. Antinociceptive activity of 4-amino-2-meth-
yl-6-phenyl-5-vinyl-3(2H)-pyridazinonewhich was found 
to be many fold potent than the emorfazone. A series of 
2/3-substituted-6(4-methylphenyl)-4,5-dihydro-pyridaz-
in3(2H)-ones and Pyridazine substituted Triazine were 
developed that allow efficient preparation of analogues 
with varied substitutions on the pyridazinone ring [28].
Somepyridazine derivatives were evaluation of their an-
algesic and anti-inflammatory activities to obtainesafer 
non-steroidal anti-inflammatory agents (NSAIDs). The 
aryl propionic acid on reaction with phenyl hydrazine and 
hydrazine hydrate yielded the pyridazinone derivative, 
6-(4-Methylphenyl)-2-phenylpyridazin-3(2H)-one (1) and 
6-(4-Methylphenyl)-4,5-dihydropyridazin-3(2H)-one (2), 
respectively. The reaction of the compound 2 with phos-
phorus oxychloride (POCl3) produced the correspond-
ing chloropyridazine derivative, 3-Chloro-6-(4-methyl-
phenyl)-pyridazine (3). A 2-(Hydroxymethyl)-6-(4-methyl-
phenyl)-4,5-dihydropyridazin-3(2H)-one (4)was synthe-
sized by condensing 2 with methanol and formaldehyde 
(HCHO). The compound 4 on further treatment with
guanidine hydrochloride in ethanol gave the pyridazi-
no-triazine, 7-(4-methylphenyl)-3,4,8,9-tetrahydro-2H-pyr-
idazino[1,6-á][1,3,5]triazin-2-imine (5). The compounds 
were tested for their analgesic activity in mice and 
anti-inflammatory activity in Wistar albino rats. The results 
of in-vivo anti-inflammatory studies revealed that the com-
pound 3 showed maximum inhibition in paw edema volume 
followed by compound 2 while the compound 3 exhibited 
excellent peripheral analgesic activity (74%) followed of 
the compound 4. Compounds 3 and 4 also showed a good 
central analgesic effect increased the reaction time to 90 
minutes [28]. 
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Compounds, 2 and 3, had smaller paw volume than the 
positive control and were found to be more potent. All the 
tested compounds except compound 4 exhibited the maxi-
mum reduction in paw volume at 120 min while 4 displayed 
the maximum protection at 90 min. It could be concluded 
that the anti-inflammatory activity of the synthesized com-
pounds could be due to the inhibition of inflammatory me-
diators release and possibly due to the inhibition of COX 
synthesis similar to indomethacin. It was observed that 
substitution of 2-phenyl ring at p-position with –CH2OH 
in compound 4 decreases the anti-inflammatory activity. 
However, the best activity is shown by compound (2) hav-
ing no substituent at second position of pyridazine ring.
Further, replacing an oxo group at third position with a 
-chloro group does not lead to change in the activity. Com-
pound (3) was found to be the most potent analgesic agent 
with respect to standard drug. Other compounds also 
showed moderate to good analgesic activity. The results in-
dicated that pyridazine derivatives possess significant an-
algesic activity associated with NSAIDs properties. All title 
compounds exhibited anti-inflammatory activity that lasted 
for 90 min and the potency increased with time. Among the 
synthesized pyridazinones, compound 3 emerged as lead 
compound with good analgesic and anti-inflammatory activ-
ities at par with the reference drug. Most of the compounds 
were exhibited and analgesic effect by both peripheral and 
central mechanisms. The anti-inflammatory and analge-
sic potential of 2/3 substituted pyridazine derivatives was 
confirmed. However, further detailed investigations are 
needed to establish the safety, efficacy and mechanism 
of this promising class of heterocyclic compounds [28]. 
Antimicrobial activity: A series of 3-substituted phe-
nyl-6-substituted phenyl(1,2,4)triazolo(4,3-b) pyridazine 
has been synthesized. The corresponding aroyl propionic 
acid was cyclised with hydrazine hydrate to give 6-(substi-
tuted aryl)-2,3,4,5-tetrahydro-3-pyridazinone, which was 
heated on steam bath with phosphorous oxy chloride to 
yield 3-chloro-6-substituted phenyl pyridazine. This inter-
mediate after reaction with hydrazine hydrate was convert-
ed into 3-hydrazino-6-substituted phenyl pyradazine. The 
resulting product was converted into 3-substituted phenyl 
6-substituted phenyl(1,2,4)triazolo(4,3-b)pyridazine by 
reacting with substituted aroyl chloride. The synthesized 
compounds were investigated for their in vitro antifungal 
and antibacterial activities. The results indicated that the 
synthesized compounds have mild to potent activities with
reference to their appropriate reference standards [29].
The synthesized 3-phenyl 6-(4’-tolyl) (1,2,4) triazolo (4,3-
b) pyridazine (6a), 3,6-di(4’-tolyl) (1,2,4)triazolo(4,3-b) 
pyridazine (6b), 3-phenyl 6-(2’,4’-dimethyl phenyl)(1,2,4) 
triazolo(4,3-b) pyridazine (7a), 3-(4’-tolyl)-6-(2’,4’-dimeth-
yl phenyl)(1,2,4) triazolo(4,3-b)pyridazine (7b), 3-phe-
nyl6-(4’-phenoxyphenyl)(1,2,4)triazolo(4,3-b)pyridazine 
(8a).3-(4’-tolyl)-6-(4’-phenoxyphenyl)(1,2,4)triazolo(4,3-b) 
pyridazine (8b), 3-phenyl 6-(4’-chloro phenyl)(1,2,4) tri-
azolo(4,3-b)pyridazine (9a), 3-(4’-tolyl)-6-(4’-chloro phe-
nyl)(1,2,4) triazolo(4,3-b) pyridazine (9b), 3-phenyl-6-
(4’-bromo phenyl)(1,2,4)triazolo(4,3-b)pyridazine (10a) 
and 3-(4’-tolyl)-6-(4’-bromo phenyl)(1,2,4)triazolo (4,3-b)
pyridazine (10b) compounds were evaluated for their anti-
bacterial activity against EscherichiaColi, Staphylococcus 
aureus, Micrococcus luteus and Klebsiella pneumonia. 
The results of antibacterial exhibit that all compounds 
having comparable activity against the bacterial strain. 
Compounds 6b, 7b and 8b are the most active deriva-
tives, which shows significant activity against these bac-
teria comparable to standard drug, ampicillin and chlor-
amphenicol. All the final compounds were evaluated for 
antifungal activity against Candidaalbicans and Can-
didaneoformans and compared with standard drug fluco-
nazole. The compounds 7a, 7b and 9b were found to be 
active derivatives of this series against the microorganism.
It is concluded that compounds 6b, 7b and 8b are active 
against gram positive and gram negative bacteria. Com-
pound 7a, 7b and 9b are potent antifungal drugs [29].
The 6-substituted phenyl-2-[{(4’-substituted phenyl-
5 ’ - t h i oxo ) -1 ,2 ,4 - t r i azo l - 3 - y l } -me thy l ] - 2 ,3 ,4 ,5 -
tetrahydropyridazin-3-one (11-20) compounds were tested 
for their in vitro antifungal activity on five fungal species, 
namely Candida albicans, Trichophyton rubrum, Aspergillus 
flavus, Aspergillus niger and Penicillium citrinium.
The antifungal activities of the 6-Substituted-2-{[(4’-
substituted-phenyl-5íthioxo)-1,2,4-triazol-3-yl]-methyl]-
2,3,4,5-tetrahydropyridazin-3-one compounds (11-20) 
against different Candida albicans, Trichophyton rubrum, 
Aspergillus flavus, Aspergillus niger and Penicillium 
citrinium fungal species and the results were compared with 
the standard drug voriconazole. The MIC of voriconazole 
for all the fungal species was lower than 0.5μg/mL. All 
compounds were found significant antifungal activities 
against all the fungal species. The chloro substituent 
derivative (17) showed the highest activity against all the 
fungal species. The MIC of the voriconazole was between 
0.10 and 0.50 μg/ml against all the fungal species. The two 
electronegative groups of Cl was increasing the activity 
of 1,2,4-triazole.The bulky group or aromatic group on 
benzene ring decreased the activity.
Anticancer activity: The triazolo[4,3-b]pyridazinones 
were evaluated for their potential in vitro cytotoxic 
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antitumor properties. The compounds were prepared 
by 1,3-dipolar cyclo addition of pyridazin-3-ones with 
N-aryl-C-ethoxycarbonylnitrile imines, generated in situ 
from ethylhydrazono-α-bromoglyoxylates.
The triazolo[4,3-b]pyridazinones (21-27) have been 
synthesized with the aim to evaluate their cytotoxic activity 
against tumor cells. Cells (105/ml) were treated with 
increasing concentrations of compounds 22-24, followed 
by 48 h incubation. In vitro evaluation of the cytotoxic 
effect of compounds 23 and 24 showed that both of these 
30
Scheme 1. Synthesis of 2-amino-2-(6-chloro-[1,2,4]triazolo[4,3-b]pyridazin-3-yl) acetic acid from ethyl 
2-(benzamido)-2-(6-chloro-[1,2,4]triazolo[4,3-b]pyridazin-3-yl) acetate.
Scheme 2. Synthesis of 2-amino-2-(6-chloro-[1,2,4]triazolo[4,3-b]pyridazin-3-yl) acetic acid  and N-((6-hydroxy-[1,2,4]
triazolo[4,3-b]pyridazin-3-yl)methyl) benzamide from ethyl 2-(benzamido)-2-(6-chloro-[1,2,4]triazolo[4,3-b]pyridaz-
in-3-yl) acetate.
Scheme 3. Synthesis of 2-((6-chloro-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)methyl) isoindoline-1,3-dione 
and (6-chloro-[1,2,4]triazolo[4,3-b]pyridazin-3-yl) methanamine
Scheme 4. Synthesis of 2-(benzamido)-2-(6-chloro-[1,2,4]triazolo[4,3-b]pyridazin-3-yl) acetic acid, N-((6-chloro-[1,2,4]
triazolo[4,3-b]pyridazin-3-yl)methyl) benzamide and compound (XI) from ethyl 2-(benzamido)-2-(6-chloro-[1,2,4]tri-
azolo[4,3-b]pyridazin-3-yl) acetate (I).
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Scheme 5. Preparation of N-Benzoyl-(6-hydrazino[1,2,4] triazolo [4,3,-b] pyridazin -3-yl) glycine hydrazide and 
2-Hydroxyethyl N-benzoyl –(6-chloro [1,2,4] triazolo [4,3-b] pyridazin-3-yl) glycinate 
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products are cytotoxic to the HepA cell line in a dose-
dependent manner, with IC50 values of 20.76 μg ml-1 and 
9.2 μg ml-1, respectively. It is noteworthy that the cytotoxic 
effect of these products is weaker than that induced by 
adriamycin (IC50:1.2 μg ml-1). The compound 24 was more 
cytotoxic than compound 23. Compound 24 exhibited 
significant cytotoxicity against the Hep cell line [31].
Synthesis: The preparation of some derivatives of 
the [1,2,4]triazolo[4,3-b]pyridazine system from ethyl 
N-benzoyl-(6-chloro[1,2,4]triazolo[4,3-b]pyridazin-3-
yl)glycinate is reported [32]. A general approach to 
ethyl N-benzoyl-α-hetero-aryl-glycinates based on the 
annulation of the 1,2,4-triazole ring on the suitably 
substituted azine or fused azine derivative (Scheme 1). 
The [1,2,4]triazolo[4,3-b]pyridazine system has attracted 
great attention, it explore synthetic utility of compound I 
in the preparation of some other derivatives. In particular, 
interest in the preparation of the amino acid II [21].
Reaction of I with hot 1 M sodium hydroxide solution took 
place on the ethoxycarbonyl group and at the position 6 of 
the triazolopyridazine system to give III, which underwent 
decarboxylation in hot ethanol affording benzamide IV 
(Scheme 2) [21].
Refluxing of I in diluted hydrochloric acid (1:1) for 4 h gave 
hydrochloride V. This compound was also prepared via 
a longer reaction sequence starting from hydrazide VI 
which was firstly transformed by heating in acetic acid 
into the chloromethyl substituted triazolopyridazine VII. 
Substitution of the chloro group with potassium phthalimide 
in hot N,N-dimethylformamide produced VIII, which 
hydrolyzed in hot hydrochloric acid to give V (Scheme 3).
On the other hand, treatment of I with concentrated 
hydrochloric acid at room temperature for 15 days yielded 
acid IX, which similarly as III underwent decarboxylation 
by heating in ethanol giving benzamide X. The latter 
was also prepared by oxidative cyclization of hydrazone 
XI [34]. Evidently, strong reaction conditions required 
for the elimination of the protective groups caused the 
decarboxylation of IX making impossible the preparation 
of the acid II (Scheme 4).
Stable triazolopyridazine were obtained in reactions of 
1 with hydrazine hydrate and ethylene glycol. Reaction 
with hot 80% hydrazine hydrate proceeded similarly as 
with sodium hydroxide at two electron deficient carbons, 
carbon 6 and carbonyl group, giving hydrazide XII, 
whereas treatment with hot ethylene glycol resulted in the 
formation of XIII. Both products might be suitable starting 
compounds for the preparation of some tricyclic systems, 
the former also for the peptide synthesis (Scheme 5).
CONCLUSION
Pyridazine is an important heterocyclic scaffold for 
designing medicinal agents with varying biological actions. 
The easy functionalization at various ring positions makes 
them an attractive synthetic building block for designing, 
synthesis and discovery of new drugs. The incorporation 
of this versatile biologically accepted pharmacophore in 
established medicinally active molecules results in wide 
range of pharmacological effects. Further optimization of 
the chemical synthesis can possibly lead to more active 
molecules against fungal infections. Since all twelve 
compounds showed promising results, studies to establish 
their in vivo efficacy will be carried in the future. 
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